Excalipoint Therapeutics completed a $68.7 million seed financing round.
- Amount
- $68.7M
- Stage
- Seed
- Announced
- 18 March 2026
- Leads
- HSG, Apricot Capital, Yuanbio Venture Capital, MPCi (formerly Matrix Partners China), Centurium Capital
- Other investors
- 5Y Capital, Co-Win Ventures, Med-Fine Capital, Hony Capital, LAV (Lilly Asia Ventures), Eisai Innovation Inc
- Use of funds
- Advancement of proprietary technology platforms and a pipeline of differentiated T-cell engager programs.
- Checked
- Amount and date checked against the press source